GAMMA Investing LLC Has $212,000 Stock Holdings in Revvity, Inc. (NYSE:RVTY)

GAMMA Investing LLC boosted its stake in Revvity, Inc. (NYSE:RVTY) by 10.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 1,898 shares of the company’s stock after buying an additional 185 shares during the period. GAMMA Investing LLC’s holdings in Revvity were worth $212,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of RVTY. Gladius Capital Management LP bought a new stake in shares of Revvity in the third quarter valued at about $32,000. EverSource Wealth Advisors LLC boosted its holdings in Revvity by 74.2% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 392 shares of the company’s stock valued at $41,000 after purchasing an additional 167 shares during the period. Fairfield Financial Advisors LTD acquired a new position in shares of Revvity during the 2nd quarter worth approximately $43,000. Continuum Advisory LLC raised its position in shares of Revvity by 2,972.7% in the third quarter. Continuum Advisory LLC now owns 338 shares of the company’s stock valued at $43,000 after buying an additional 327 shares in the last quarter. Finally, Avior Wealth Management LLC boosted its stake in shares of Revvity by 7,980.0% in the third quarter. Avior Wealth Management LLC now owns 404 shares of the company’s stock valued at $52,000 after buying an additional 399 shares during the period. 86.65% of the stock is owned by institutional investors.

Revvity Price Performance

Revvity stock opened at $116.55 on Wednesday. The stock has a 50-day moving average price of $115.67 and a two-hundred day moving average price of $116.81. Revvity, Inc. has a 12 month low of $97.32 and a 12 month high of $129.50. The company has a market capitalization of $14.18 billion, a PE ratio of 56.30, a P/E/G ratio of 3.59 and a beta of 1.03. The company has a current ratio of 3.56, a quick ratio of 2.97 and a debt-to-equity ratio of 0.40.

Revvity (NYSE:RVTY) last issued its quarterly earnings data on Monday, November 4th. The company reported $1.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.13 by $0.15. Revvity had a net margin of 9.34% and a return on equity of 7.42%. The business had revenue of $684.10 million during the quarter, compared to analyst estimates of $679.66 million. During the same quarter last year, the business earned $1.18 EPS. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. Analysts expect that Revvity, Inc. will post 4.85 EPS for the current year.

Revvity announced that its Board of Directors has authorized a stock repurchase plan on Monday, November 4th that authorizes the company to repurchase $1.00 billion in shares. This repurchase authorization authorizes the company to buy up to 6.5% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s management believes its stock is undervalued.

Revvity Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, February 7th. Shareholders of record on Friday, January 17th will be issued a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.24%. The ex-dividend date of this dividend is Friday, January 17th. Revvity’s payout ratio is presently 13.53%.

Wall Street Analysts Forecast Growth

RVTY has been the topic of a number of recent research reports. Sanford C. Bernstein lowered their price objective on Revvity from $150.00 to $145.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 5th. Barclays dropped their target price on shares of Revvity from $140.00 to $135.00 and set an “overweight” rating for the company in a research report on Monday, November 25th. Bank of America upgraded shares of Revvity from a “neutral” rating to a “buy” rating and set a $138.00 price target on the stock in a research report on Friday, December 13th. Leerink Partners upped their target price on Revvity from $130.00 to $135.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Finally, Raymond James lifted their price target on Revvity from $144.00 to $146.00 and gave the company an “outperform” rating in a research note on Tuesday, November 5th. Five investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Revvity currently has an average rating of “Moderate Buy” and an average target price of $133.00.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.